Given the recent breakthrough of NGS techniques, such as WES, we reckon that the analysis of FGFR2 should be included, and its variants should be taken in mind in patients with neurodevelopmental disorder, especially in association with craniosynostosis and body overgrowth. This evidence concerns the gene FGFR2 and craniosynostosis.